Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Dec;8(Suppl 4):S383-S386.
doi: 10.21037/tlcr.2019.05.10.

Lorlatinib: an additional option for ALK-positive non-small cell lung cancer?

Alice Mogenet  1 , Pascale Tomasini  1 , Laurent Greillier  1 , Fabrice Barlesi  1
Affiliations
Editorial

Lorlatinib: an additional option for ALK-positive non-small cell lung cancer?

Alice Mogenet et al. Transl Lung Cancer Res. 2019 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: F Barlesi: Astra-Zeneca, Bayer, Bristol-Myers Squibb, Boehringer–Ingelheim, Eli Lilly Oncology, F. Hoffmann–La Roche Ltd, Novartis, Merck, MSD, Pierre Fabre, Pfizer and Takeda. The other authors have no conflicts of interest to declare.

Comment on

References

    1. Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29. 10.3322/caac.21208 - DOI - PubMed
    1. Chia PL, Mitchell P, Dobrovic A, et al. Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors. Clin Epidemiol 2014;6:423-32. 10.2147/CLEP.S69718 - DOI - PMC - PubMed
    1. Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368:2385-94. 10.1056/NEJMoa1214886 - DOI - PubMed
    1. Solomon BJ, Mok T, Kim DW, et al. First-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer. N Engl J Med 2014;371:2167-77. 10.1056/NEJMoa1408440 - DOI - PubMed
    1. Soria JC, Tan DSW, Chiari R, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet 2017;389:917-29. 10.1016/S0140-6736(17)30123-X - DOI - PubMed

LinkOut - more resources